Internal Medicine Alert – October 30, 2014
October 30, 2014
View Issues
-
LDL Levels — Are Fasting Blood Specimens Necessary?
Doran B, et al. Prognostic value of fasting versus nonfasting low-density lipoprotein cholesterol levels on long-term mortality: Insight from the National Health and Nutrition Examination Survey III -
Migraines: Much More Complicated Than Just a Headache
Migraine is associated with multiple disorders, including irritable bowel syndrome, restless legs syndrome, and non-alcoholic fatty liver disease. Understanding how these disparate disorders link to migraine may lead to an increased understanding of the pathogenesis of this complex neurological condition. -
Angiotensin Receptor Blockers for Hypertension
Makani H, et al. Antihypertensive efficacy of angiotensin receptor blockers as monotherapy as evaluated by ambulatory blood pressure monitoring: A meta-analysis. -
Naloxegol Tablets (Movantik ¢â )
The FDA has approved a mu-opioid receptor antagonist for the treatment of opioid-induced constipation (OIC). Naloxegol is a pegylated derivative of naloxone which acts on peripheral (e.g., gut) mu-receptors. It is marketed by AstraZeneca Pharmaceuticals as Movantik. -
Hepatitis C Treatment: Just How Much is it Worth to Cure a Dreadful Disease?
The trouble with the expense of treating hepatitis C virus (HCV) infections is that very few patients are acutely choking on it, since the largest pool of HCV patients are asymptomatic. Progression to end-stage liver disease, liver transplantation, and hepatocellular carcinoma the three most dreaded HCV consequences may seem distant to the asymptomatic or even modestly symptomatic patient.